Skip to main content
Log in

Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes

  • Review
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

Interindividual variability in oral drug efficacy and toxicity is commonly observed in all therapeutic areas. Importantly, interindividual variability in drug uptake and metabolism can result in poor drug response, adverse drug reactions, or unfavorable drug-drug interaction. One of the common causes of individual variations in drug response is genetic variation of drug transporters and metabolizing enzymes. Pharmacogenetics are rapidly elucidating the inherited nature of these differences in drug disposition and effects, thereby providing a stronger scientific basis for optimizing drug therapy on the basis of each patient’s genetic constitution. Knowledge of the genotype-phenotype correlation and frequency distribution of functional single nucleotide polymorphisms may be a valuable tool for individualizing drug therapy. This information can also be useful for explaining inter-individual and inter-ethnic variations in drug response and/or adverse effects. In this review, we focus on the interplay between efflux transporter (ATP-binding cassette, sub-family B (MDR/TAP), member 1/ABCB1) and cytochrome P450s according to genetic polymorphism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adedoyin, A., Prakash, C., O’shea, D., Blair, I. A., and Wilkinson, G. R., Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics, 4, 27–38 (1994).

    PubMed  CAS  Google Scholar 

  • Amidon, G. L., Lennernas, H., Shah, V. P., and Crison, J. R., A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 12, 413–420 (1995).

    PubMed  CAS  Google Scholar 

  • Ayrton, A. and Morgan, P., Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica, 31, 469–497 (2001).

    PubMed  CAS  Google Scholar 

  • Badhan, R., Penny, J., Galetin, A., and Houston, J. B., Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. J. Pharm. Sci., 98, 2180–2197 (2009).

    PubMed  CAS  Google Scholar 

  • Ball, S. E., Scatina, J., Kao, J., Ferron, G. M., Fruncillo, R., Mayer, P., Weinryb, I., Guida, M., Hopkins, P. J., Warner, N., and Hall, J., Population distribution and effects on drug metabolism of a genetic variant in the 5’ promoter region of CYP3A4. Clin. Pharmacol. Ther., 66, 288–294 (1999).

    PubMed  CAS  Google Scholar 

  • Balram, C., Zhou, Q., Cheung, Y. B., and Lee, E. J., CYP3A5 *3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur. J. Clin. Pharmacol., 59, 123–126 (2003).

    PubMed  CAS  Google Scholar 

  • Benet, L. Z. and Cummins, C. L., The drug efflux-metabolism alliance: biochemical aspects. Adv. Drug Deliv. Rev., 50, S3–S11 (2001).

    PubMed  CAS  Google Scholar 

  • Benet, L. Z., Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System. Basic Clin. Pharmacol. Toxicol., 106, 162–167 (2010).

    PubMed  CAS  Google Scholar 

  • Bertilsson, L., Lou, Y. Q., Du, Y. L., Liu, Y., Kuang, T. Y., Liao, X. M., Wang, K. Y., Reviriego, J., Iselius, L., and Sjoqvist, F., Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther., 51, 388–397 (1992).

    PubMed  CAS  Google Scholar 

  • Cascorbi, I., Gerloff, T., Johne, A., Meisel, C., Hoffmeyer, S., Schwab, M., Schaeffeler, E., Eichelbaum, M., Brinkmann, U., and Roots, I., Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther., 69, 169–174 (2001).

    PubMed  CAS  Google Scholar 

  • Chen, M. L., Shah, V., Patnaik, R., Adams, W., Hussain, A., Conner, D., Mehta, M., Malinowski, H., Lazor, J., Huang, S. M., Hare, D., Lesko, L., Sporn, D., and Williams, R., Bioavailability and bioequivalence: an FDA regulatory overview. Pharm. Res., 18, 1645–1650 (2001).

    PubMed  CAS  Google Scholar 

  • Cho, H. Y., Park, S. A., and Lee, Y. B., Improvement and validation of an HPLC method for examining the effects of the MDR1 gene polymorphism on sparfloxacin pharmacokinetics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 834, 84–92 (2006).

    PubMed  CAS  Google Scholar 

  • Cho, H. Y., Yoon, H., Park, G. K., and Lee, Y. B., Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, twoperiod, two-sequence crossover study in healthy Korean male volunteers. Clin. Ther., 31, 2712–2721 (2009).

    PubMed  CAS  Google Scholar 

  • Cho, H. Y., Yoo, H. D., and Lee, Y. B., Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects. Neuroscience, 169, 378–387 (2010).

    PubMed  CAS  Google Scholar 

  • Chowbay, B., Cumaraswamy, S., Cheung, Y. B., Zhou, Q., and Lee, E. J., Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics, 13, 89–95 (2003).

    PubMed  CAS  Google Scholar 

  • Croop, J. M., Raymond, M., Haber, D., Devault, A., Arceci, R. J., Gros, P., and Housman, D. E., The three mouse multidrug resistance (mdr) genes are expressed in a tissuespecific manner in normal mouse tissues. Mol. Cell. Biol., 9, 1346–1350 (1989).

    PubMed  CAS  Google Scholar 

  • Daly, A. K., Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol., 17, 27–41 (2003).

    PubMed  CAS  Google Scholar 

  • Darwich, A. S., Neuhoff, S., Jamei, M., and Rostami-Hodjegan, A., Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” model. Curr. Drug Metab., 11, 716–729 (2010).

    PubMed  CAS  Google Scholar 

  • De Morais, S. M., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K., and Goldstein, J. A., Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol., 46, 594–598 (1994a).

    PubMed  Google Scholar 

  • De Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., and Goldstein, J. A., The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem., 269, 15419–15422 (1994b).

    PubMed  Google Scholar 

  • Devault, A. and Gros, P., Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol. Cell. Biol., 10, 1652–1663 (1990).

    PubMed  CAS  Google Scholar 

  • Domanski, T. L., Finta, C., Halpert, J. R., and Zaphiropoulos, P. G., cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol. Pharmacol., 59, 386–392 (2001).

    PubMed  CAS  Google Scholar 

  • Drescher, S., Schaeffeler, E., Hitzl, M., Hofmann, U., Schwab, M., Brinkmann, U., Eichelbaum, M., and Fromm, M. F., MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol., 53, 526–534 (2002).

    PubMed  CAS  Google Scholar 

  • Eiselt, R., Domanski, T. L., Zibat, A., Mueller, R., Presecan-Siedel, E., Hustert, E., Zanger, U. M., Brockmoller, J., Klenk, H. P., Meyer, U. A., Khan, K. K., He, Y. A., Halpert, J. R., and Wojnowski, L., Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics, 11, 447–458 (2001).

    PubMed  CAS  Google Scholar 

  • Evans, W. E. and Mcleod, H. L., Pharmacogenomics—drug disposition, drug targets, and side effects. N. Engl. J. Med., 348, 538–549 (2003).

    PubMed  CAS  Google Scholar 

  • Fellay, J., Marzolini, C., Meaden, E. R., Back, D. J., Buclin, T., Chave, J. P., Decosterd, L. A., Furrer, H., Opravil, M., Pantaleo, G., Retelska, D., Ruiz, L., Schinkel, A. H., Vernazza, P., Eap, C. B., and Telenti, A., Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet, 359, 30–36 (2002).

    PubMed  CAS  Google Scholar 

  • Frohlich, M., Hoffmann, M. M., Burhenne, J., Mikus, G., Weiss, J., and Haefeli, W. E., Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. Br. J. Clin. Pharmacol., 58, 443–444 (2004).

    PubMed  Google Scholar 

  • Galetin, A. and Houston, J. B., Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J. Pharmacol. Exp. Ther., 318, 1220–1229 (2006).

    PubMed  CAS  Google Scholar 

  • Gan, S. H., Ismail, R., Wan Adnan, W. A., and Wan, Z., Correlation of tramadol pharmacokinetics and CYP2D6*10 genotype in Malaysian subjects. J. Pharm. Biomed. Anal., 30, 189–195 (2002).

    PubMed  CAS  Google Scholar 

  • Gerloff, T., Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution. Naunyn. Schmiedebergs Arch. Pharmacol., 369, 69–77 (2004).

    PubMed  CAS  Google Scholar 

  • Goldstein, J. A., Ishizaki, T., Chiba, K., De Morais, S. M., Bell, D., Krahn, P. M., and Evans, D. A., Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 7, 59–64 (1997).

    PubMed  CAS  Google Scholar 

  • Goto, M., Masuda, S., Saito, H., Uemoto, S., Kiuchi, T., Tanaka, K., and Inui, K., C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics, 12, 451–457 (2002).

    PubMed  CAS  Google Scholar 

  • Haufroid, V., Mourad, M., Van Kerckhove, V., Wawrzyniak, J., De Meyer, M., Eddour, D. C., Malaise, J., Lison, D., Squifflet, J. P., and Wallemacq, P., The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics, 14, 147–154 (2004).

    PubMed  CAS  Google Scholar 

  • Hesselink, D. A., Van Gelder, T., Van Schaik, R. H., Balk, A. H., Van Der Heiden, I. P., Van Dam, T., Van Der Werf, M., Weimar, W., and Mathot, R. A., Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther., 76, 545–556 (2004).

    PubMed  CAS  Google Scholar 

  • Hesselson, S. E., Matsson, P., Shima, J. E., Fukushima, H., Yee, S. W., Kobayashi, Y., Gow, J. M., Ha, C., Ma, B., Poon, A., Johns, S. J., Stryke, D., Castro, R. A., Tahara, H., Choi, J. H., Chen, L., Picard, N., Sjodin, E., Roelofs, M. J., Ferrin, T. E., Myers, R., Kroetz, D. L., Kwok, P. Y., and Giacomini, K. M., Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PloS One, 4, e6942 (2009).

    PubMed  Google Scholar 

  • Higgins, C. F., ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol., 8, 67–113 (1992).

    PubMed  CAS  Google Scholar 

  • Hitzl, M., Drescher, S., Van Der Kuip, H., Schaffeler, E., Fischer, J., Schwab, M., Eichelbaum, M., and Fromm, M. F., The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics, 11, 293–298 (2001).

    PubMed  CAS  Google Scholar 

  • Hoffmeyer, S., Burk, O., Von Richter, O., Arnold, H. P., Brockmoller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., and Brinkmann, U., Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with Pglycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A., 97, 3473–3478 (2000).

    PubMed  CAS  Google Scholar 

  • Hsu, S. I., Lothstein, L., and Horwitz, S. B., Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. Evidence that distinct P-glycoprotein precursors are encoded by unique mdr genes. J. Biol. Chem., 264, 12053–12062 (1989).

    PubMed  CAS  Google Scholar 

  • Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y. Q., Klein, K., Nuessler, A. C., Neuhaus, P., Klattig, J., Eiselt, R., Koch, I., Zibat, A., Brockmoller, J., Halpert, J. R., Zanger, U. M., and Wojnowski, L., The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics, 11, 773–779 (2001).

    PubMed  CAS  Google Scholar 

  • Johansson, I., Oscarson, M., Yue, Q. Y., Bertilsson, L., Sjoqvist, F., and Ingelman-Sundberg, M., Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol., 46, 452–459 (1994).

    PubMed  CAS  Google Scholar 

  • Johne, A., Kopke, K., Gerloff, T., Mai, I., Rietbrock, S., Meisel, C., Hoffmeyer, S., Kerb, R., Fromm, M. F., Brinkmann, U., Eichelbaum, M., Brockmoller, J., Cascorbi, I., and Roots, I., Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther., 72, 584–594 (2002).

    PubMed  CAS  Google Scholar 

  • Johnson, B. M., Charman, W. N., and Porter, C. J., Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A. Drug Metab. Dispos., 31, 1151–1160 (2003).

    PubMed  CAS  Google Scholar 

  • Kerb, R., Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett., 234, 4–33 (2006).

    PubMed  CAS  Google Scholar 

  • Kim, K. A., Park, P. W., Hong, S. J., and Park, J. Y., The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin. Pharmacol. Ther., 84, 236–242 (2008).

    PubMed  CAS  Google Scholar 

  • Kim, R. B., Leake, B. F., Choo, E. F., Dresser, G. K., Kubba, S. V., Schwarz, U. I., Taylor, A., Xie, H. G., Mckinsey, J., Zhou, S., Lan, L. B., Schuetz, J. D., Schuetz, E. G., and Wilkinson, G. R., Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther., 70, 189–199 (2001).

    PubMed  CAS  Google Scholar 

  • Kim, R. B., MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics, 12, 425–427 (2002a).

    PubMed  CAS  Google Scholar 

  • Kim, R. B., Transporters and xenobiotic disposition. Toxicology, 181–182, 291–297 (2002b).

    PubMed  Google Scholar 

  • Kimchi-Sarfaty, C., Gribar, J. J., and Gottesman, M. M., Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol., 62, 1–6 (2002).

    PubMed  CAS  Google Scholar 

  • Kimchi-Sarfaty, C., Oh, J. M., Kim, I. W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., and Gottesman, M. M., A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science, 315, 525–528 (2007).

    PubMed  CAS  Google Scholar 

  • Kirschbaum, K. M., Henken, S., Hiemke, C., and Schmitt, U., Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav. Brain Res., 188, 298–303 (2008).

    PubMed  CAS  Google Scholar 

  • Kivisto, K. T., Niemi, M., Schaeffeler, E., Pitkala, K., Tilvis, R., Fromm, M. F., Schwab, M., Eichelbaum, M., and Strandberg, T., Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics, 14, 523–525 (2004).

    PubMed  Google Scholar 

  • Klotz, U., Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int. J. Clin. Pharmacol. Ther., 44, 297–302 (2006).

    PubMed  CAS  Google Scholar 

  • Kroetz, D. L., Pauli-Magnus, C., Hodges, L. M., Huang, C. C., Kawamoto, M., Johns, S. J., Stryke, D., Ferrin, T. E., Deyoung, J., Taylor, T., Carlson, E. J., Herskowitz, I., Giacomini, K. M., and Clark, A. G., Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics, 13, 481–494 (2003).

    PubMed  CAS  Google Scholar 

  • Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., Yasuda, K., Venkataramanan, R., Strom, S., Thummel, K., Boguski, M. S., and Schuetz, E., Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 27, 383–391 (2001).

    PubMed  CAS  Google Scholar 

  • Kuypers, D. R., De Jonge, H., Naesens, M., and Vanrenterghem, Y., Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet. Genomics, 18, 861–868 (2008).

    PubMed  CAS  Google Scholar 

  • Lee, C. G., Gottesman, M. M., Cardarelli, C. O., Ramachandra, M., Jeang, K. T., Ambudkar, S. V., Pastan, I., and Dey, S., HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry (Mosc.), 37, 3594–3601 (1998).

    CAS  Google Scholar 

  • Lee, S. J., Usmani, K. A., Chanas, B., Ghanayem, B., Xi, T., Hodgson, E., Mohrenweiser, H. W., and Goldstein, J. A., Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics, 13, 461–472 (2003).

    PubMed  CAS  Google Scholar 

  • Lee, V. H., Membrane transporters. Eur. J. Pharm. Sci., 11, 41–50 (2000).

    Google Scholar 

  • Lepper, E. R., Baker, S. D., Permenter, M., Ries, N., Van Schaik, R. H., Schenk, P. W., Price, D. K., Ahn, D., Smith, N. F., Cusatis, G., Ingersoll, R. G., Bates, S. E., Mathijssen, R. H., Verweij, J., Figg, W. D., and Sparreboom, A., Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin. Cancer Res., 11, 7398–7404 (2005).

    PubMed  CAS  Google Scholar 

  • Leslie, E. M., Deeley, R. G., and Cole, S. P., Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol., 204, 216–237 (2005).

    PubMed  CAS  Google Scholar 

  • Llerena, A., Dorado, P., O’kirwan, F., Jepson, R., Licinio, J., and Wong, M. L., Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. Pharmacogenomics J., 4, 403–406 (2004).

    PubMed  CAS  Google Scholar 

  • Macphee, I. A., Fredericks, S., Tai, T., Syrris, P., Carter, N. D., Johnston, A., Goldberg, L., and Holt, D. W., Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation, 74, 1486–1489 (2002).

    PubMed  CAS  Google Scholar 

  • Macphee, I. A., Fredericks, S., Mohamed, M., Moreton, M., Carter, N. D., Johnston, A., Goldberg, L., and Holt, D. W., Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation, 79, 499–502 (2005).

    PubMed  CAS  Google Scholar 

  • Maeda, K. and Sugiyama, Y., Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab. Pharmacokinet., 23, 223–235 (2008).

    PubMed  CAS  Google Scholar 

  • Mai, I., Perloff, E. S., Bauer, S., Goldammer, M., Johne, A., Filler, G., Budde, K., and Roots, I., MDR1 haplotypes derived from exons 21 and 26 do not affect the steadystate pharmacokinetics of tacrolimus in renal transplant patients. Br. J. Clin. Pharmacol., 58, 548–553 (2004).

    PubMed  CAS  Google Scholar 

  • Marzolini, C., Paus, E., Buclin, T., and Kim, R. B., Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther., 75, 13–33 (2004).

    PubMed  CAS  Google Scholar 

  • Meyer, U. A., Pharmacogenetics — five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet., 5, 669–676 (2004).

    PubMed  CAS  Google Scholar 

  • Min, D. I. and Ellingrod, V. L., C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit., 24, 400–404 (2002).

    PubMed  CAS  Google Scholar 

  • Min, D. I. and Ellingrod, V. L., Association of the CYP3A4* 1B 5’-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit., 25, 305–309 (2003).

    PubMed  CAS  Google Scholar 

  • Miners, J. O. and Birkett, D. J., Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol., 45, 525–538 (1998).

    PubMed  CAS  Google Scholar 

  • Morita, N., Yasumori, T., and Nakayama, K., Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem. Pharmacol., 65, 1843–1852 (2003).

    PubMed  CAS  Google Scholar 

  • Mouly, S. J., Matheny, C., Paine, M. F., Smith, G., Lamba, J., Lamba, V., Pusek, S. N., Schuetz, E. G., Stewart, P. W., and Watkins, P. B., Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin. Pharmacol. Ther., 78, 605–618 (2005).

    PubMed  CAS  Google Scholar 

  • Nakamura, T., Sakaeda, T., Horinouchi, M., Tamura, T., Aoyama, N., Shirakawa, T., Matsuo, M., Kasuga, M., and Okumura, K., Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther., 71, 297–303 (2002).

    PubMed  CAS  Google Scholar 

  • Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., Gunsalus, I. C., and Nebert, D. W., P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1–42 (1996).

    PubMed  CAS  Google Scholar 

  • Ozawa, S., Soyama, A., Saeki, M., Fukushima-Uesaka, H., Itoda, M., Koyano, S., Sai, K., Ohno, Y., Saito, Y., and Sawada, J., Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab. Pharmacokinet., 19, 83–95 (2004).

    PubMed  CAS  Google Scholar 

  • Pang, K. S., Maeng, H. J., and Fan, J., Interplay of transporters and enzymes in drug and metabolite processing. Mol. Pharm., 6, 1734–1755 (2009).

    PubMed  CAS  Google Scholar 

  • Ramamoorthy, Y., Tyndale, R. F., and Sellers, E. M., Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics, 11, 477–487 (2001).

    PubMed  CAS  Google Scholar 

  • Rodrigues, A. C., Rebecchi, I. M., Bertolami, M. C., Faludi, A. A., Hirata, M. H., and Hirata, R. D., High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. Braz. J. Med. Biol. Res., 38, 1389–1397 (2005).

    PubMed  CAS  Google Scholar 

  • Roh, H. K., Chung, J. Y., Oh, D. Y., Park, C. S., Svensson, J. O., Dahl, M. L., and Bertilsson, L., Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br. J. Clin. Pharmacol., 52, 265–271 (2001).

    PubMed  CAS  Google Scholar 

  • Sakaeda, T., Nakamura, T., Horinouchi, M., Kakumoto, M., Ohmoto, N., Sakai, T., Morita, Y., Tamura, T., Aoyama, N., Hirai, M., Kasuga, M., and Okumura, K., MDR1 genotyperelated pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res., 18, 1400–1404 (2001).

    PubMed  CAS  Google Scholar 

  • Sakaeda, T., Nakamura, T., and Okumura, K., Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr. Top. Med. Chem., 4, 1385–1398 (2004).

    PubMed  CAS  Google Scholar 

  • Schinkel, A. H., Mol, C. A., Wagenaar, E., Van Deemter, L., Smit, J. J., and Borst, P., Multidrug resistance and the role of P-glycoprotein knockout mice. Eur. J. Cancer, 31A, 1295–1298 (1995).

    PubMed  CAS  Google Scholar 

  • Schinkel, A. H., Wagenaar, E., Mol, C. A., and Van Deemter, L., P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest., 97, 2517–2524 (1996).

    PubMed  CAS  Google Scholar 

  • Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., and Guengerich, F. P., Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270, 414–423 (1994).

    PubMed  CAS  Google Scholar 

  • Shinkai, T., De Luca, V., Utsunomiya, K., Sakata, S., Inoue, Y., Fukunaka, Y., Hwang, R., Ohmori, O., Kennedy, J. L., and Nakamura, J., Functional polymorphism of the human multidrug resistance gene (MDR1) and polydipsia-hyponatremia in schizophrenia. Neuromolecular Med., 10, 362–367 (2008).

    PubMed  CAS  Google Scholar 

  • Shon, J. H., Yoon, Y. R., Kim, K. A., Lim, Y. C., Lee, K. J., Park, J. Y., Cha, I. J., Flockhart, D. A., and Shin, J. G., Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics, 12, 111–119 (2002).

    PubMed  CAS  Google Scholar 

  • Siegmund, W., Ludwig, K., Giessmann, T., Dazert, P., Schroeder, E., Sperker, B., Warzok, R., Kroemer, H. K., and Cascorbi, I., The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther., 72, 572–583 (2002).

    PubMed  CAS  Google Scholar 

  • Srinivas, N. R., Dual drug interactions via P-glycoprotein (Pgp)/cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil. Eur. J. Clin. Pharmacol., 64, 1135–1136 (2008).

    PubMed  Google Scholar 

  • Tada, H., Tsuchiya, N., Satoh, S., Kagaya, H., Li, Z., Sato, K., Miura, M., Suzuki, T., Kato, T., and Habuchi, T., Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant. Proc., 37, 1730–1732 (2005).

    PubMed  CAS  Google Scholar 

  • Tanabe, M., Ieiri, I., Nagata, N., Inoue, K., Ito, S., Kanamori, Y., Takahashi, M., Kurata, Y., Kigawa, J., Higuchi, S., Terakawa, N., and Otsubo, K., Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther., 297, 1137–1143 (2001).

    PubMed  CAS  Google Scholar 

  • Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., and Willingham, M. C., Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U. S. A., 84, 7735–7738 (1987).

    PubMed  CAS  Google Scholar 

  • Uhr, M., Tontsch, A., Namendorf, C., Ripke, S., Lucae, S., Ising, M., Dose, T., Ebinger, M., Rosenhagen, M., Kohli, M., Kloiber, S., Salyakina, D., Bettecken, T., Specht, M., Putz, B., Binder, E. B., Muller-Myhsok, B., and Holsboer, F., Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron, 57, 203–209 (2008).

    PubMed  CAS  Google Scholar 

  • Von Ahsen, N., Richter, M., Grupp, C., Ringe, B., Oellerich, M., and Armstrong, V. W., No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem., 47, 1048–1052 (2001).

    Google Scholar 

  • Wandel, C., Witte, J. S., Hall, J. M., Stein, C. M., Wood, A. J., and Wilkinson, G. R., CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5’-promoter region polymorphism. Clin. Pharmacol. Ther., 68, 82–91 (2000).

    PubMed  CAS  Google Scholar 

  • Wang, J. S., Ruan, Y., Taylor, R. M., Donovan, J. L., Markowitz, J. S., and Devane, C. L., The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int. J. Neuropsychopharmacol., 7, 415–419 (2004).

    PubMed  CAS  Google Scholar 

  • Ward, S. A., Helsby, N. A., Skjelbo, E., Brosen, K., Gram, L. F., and Breckenridge, A. M., The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism—a panel study. Br. J. Clin. Pharmacol., 31, 689–692 (1991).

    PubMed  CAS  Google Scholar 

  • Weinshilboum, R., Inheritance and drug response. N. Engl. J. Med., 348, 529–537 (2003).

    PubMed  Google Scholar 

  • Weiss, J., Ten Hoevel, M. M., Burhenne, J., Walter-Sack, I., Hoffmann, M. M., Rengelshausen, J., Haefeli, W. E., and Mikus, G., CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J. Clin. Pharmacol., 49, 196–204 (2009).

    PubMed  CAS  Google Scholar 

  • Westlind, A., Lofberg, L., Tindberg, N., Andersson, T. B., and Ingelman-Sundberg, M., Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5’-upstream regulatory region. Biochem. Biophys. Res. Commun., 259, 201–205 (1999).

    PubMed  CAS  Google Scholar 

  • Wu, C. Y. and Benet, L. Z., Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res., 22, 11–23 (2005).

    PubMed  CAS  Google Scholar 

  • Xie, H. G., Prasad, H. C., Kim, R. B., and Stein, C. M., CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev., 54, 1257–1270 (2002).

    PubMed  CAS  Google Scholar 

  • Yates, C. R., Zhang, W., Song, P., Li, S., Gaber, A. O., Kotb, M., Honaker, M. R., Alloway, R. R., and Meibohm, B., The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J. Clin. Pharmacol., 43, 555–564 (2003).

    PubMed  CAS  Google Scholar 

  • Yoo, H. D., Park, S. A., Cho, H. Y., and Lee, Y. B., Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects. Clin. Pharmacol. Ther., 86, 281–284 (2009).

    PubMed  CAS  Google Scholar 

  • Yoo, H. D., Cho, H. Y., and Lee, Y. B., Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1. Br. J. Clin. Pharmacol., 69, 27–37 (2010).

    PubMed  CAS  Google Scholar 

  • Yoo, H. D., Kim, M. S., Cho, H. Y., and Lee, Y. B., Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects. Eur. J. Clin. Pharmacol., 67, 889–898 (2011a).

    PubMed  CAS  Google Scholar 

  • Yoo, H. D., Lee, S. N., Kang, H. A., Cho, H. Y., Lee, I. K., and Lee, Y. B., Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10. Br. J. Pharmacol., 164, 433–443 (2011b).

    PubMed  CAS  Google Scholar 

  • Zainuddin, Z., Teh, L. K., Suhaimi, A. W., Salleh, M. Z., and Ismail, R., A simple method for the detection of CYP2C9 polymorphisms: nested allele-specific multiplex polymerase chain reaction. Clin. Chim. Acta, 336, 97–102 (2003).

    PubMed  CAS  Google Scholar 

  • Zhou, S. F., Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica, 38, 802–832 (2008).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yong-Bok Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoo, HD., Lee, YB. Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes. Arch. Pharm. Res. 34, 1817–1828 (2011). https://doi.org/10.1007/s12272-011-1104-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-011-1104-1

Key words

Navigation